A large weight loss often ends at a surgeon’s door, and a 2026 study asked what happens if the drug is still in the patient when they get there [1]. Eighty patients undergoing lipoabdominoplasty were split four ways — semaglutide continued to the day of surgery, stopped two weeks before, stopped four weeks before, and a group who had never taken it — and matched for age, BMI and surgical technique.
The 30-day complication rates fell in a straight line: 45% continuing to surgery, 30% at two weeks, 10% at four weeks, against 10% in the group who had never taken it. Wound dehiscence, infection and seroma were the events counted, and gastrointestinal intolerance and longer drain duration were also more common with ongoing use. No patient was readmitted or reoperated on. The reasonable conclusion, and the authors’ own, is that four weeks normalizes the risk — and it sits alongside the dosing questions covered in what nobody says about a higher dose.
Now divide by four. Eighty patients across four groups is 20 in each, so 45% is 9 people, 30% is 6, and 10% is 2. The gradient is clean and it is built from single-digit counts, and a difference of 9 against 2 in groups that size can move on very little. The percentages read as precise; the sample is not.
That is a reason to hold the number loosely, not to ignore the direction. Every step points the same way, the mechanism is not exotic — delayed gastric emptying, altered nutrition during rapid loss, both plausible contributors to wound healing — and a four-week gap before elective surgery costs a patient almost nothing. Cheap precautions do not need large trials behind them in the way expensive or risky ones do. The muscle question during rapid loss, covered in how much of it is muscle, is part of the same nutritional picture.
What makes this a buying question rather than a clinical one is sequence. People arrive at body contouring after months on a drug they bought online, and the seller that sold it is not part of the conversation with the surgeon. Nothing on this desk asks whether surgery is planned, which is the same disclosure gap counted in one good disclosure.
So the practical step is to tell the surgical team what you are taking and when you last took it, and to expect a four-week gap to be asked for. If that gap matters to a plan you have already paid for, the term and prepay check is the place to work out what pausing actually costs you.